

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
7 April 2005 (07.04.2005)

PCT

(10) International Publication Number  
**WO 2005/030804 A3**

(51) International Patent Classification<sup>7</sup>: C07K 5/00, 7/00,  
14/00, G01N 33/68, A61K 38/04, 38/17

(21) International Application Number:  
PCT/DK2004/000659

(22) International Filing Date:  
29 September 2004 (29.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
pa 2003 01418 30 September 2003 (30.09.2003) DK

(71) Applicant (for all designated States except US): ENKAM  
PHARMACEUTICALS A/S [DK/DK]; Fruebjergvej 3,  
DK-2100 Copenhagen Ø (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BOCK, Elisabeth  
[DK/DK]; Tonysvej 20, DK-2920 Charlottenlund (DK).  
BEREZIN, Vladimir [UA/DK]; Nørrebrogade 223, 1.th.,  
DK-2200 Copenhagen N (DK). SOROKA, Vladyslav  
[UA/DK]; Olivenlund 43, Høje Taastrup (DK).

(74) Agent: HØIBERG A/S; St. Kongensgade 59 A, DK-1264  
Copenhagen\_K (DK).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Declaration under Rule 4.17:**

— as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii)) for the following designations AE,  
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,  
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,  
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,  
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,  
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,  
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,  
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,  
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA,  
SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,  
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG)

**Published:**

— with international search report  
— before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(88) Date of publication of the international search report:  
11 August 2005

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: A METHOD OF MODULATING CELL SURVIVAL, DIFFERENTIATION AND/OR SYNAPTIC PLASTICITY

(57) Abstract: The present invention relates to a method of modulating differentiation, adhesion and/or survival of the neural cell adhesion molecule (NCAM) presenting cells by providing compounds capable of modulating the interaction between the Ig1, Ig2 and/or Ig3 modules of NCAM. The invention provides candidate compounds capable of modulating the interaction between the Ig1, Ig2 and/or Ig3 modules of NCAM by using methods for screening and testing described in the application. The invention further relates to pharmaceutical compositions comprising compounds capable of modulating the interaction between the Ig1, Ig2 and/or Ig3 modules of NCAM and to use of the pharmaceutical compositions and compounds for the modulation of differentiation, adhesion and/or survival of NCAM presenting cells.



WO 2005/030804 A3